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he stress-activated protein kinase p38 and nitric
oxide (NO) are proposed downstream effectors of
excitotoxic cell death. Although the postsynaptic
density protein PSD95 can recruit the calcium-dependent
neuronal NO synthase (nNOS) to the mouth of the calcium-
permeable NMDA receptor, and depletion of PSD95
inhibits excitotoxicity, the possibility that selective uncou-
pling of nNOS from PSD95 might be neuroprotective is
unexplored. The relationship between excitotoxic stress–
generated NO and activation of p38, and the signiﬁ-
cance of the PSD95–nNOS interaction to p38 activation
T
 
also remain unclear. We ﬁnd that NOS inhibitors reduce
both glutamate-induced p38 activation and the resulting
neuronal death, whereas NO donor has effects consistent
with NO as an upstream regulator of p38 in glutamate-
induced cell death. Experiments using a panel of decoy
constructs targeting the PSD95–nNOS interaction suggest
that this interaction and subsequent NO production are
critical for glutamate-induced p38 activation and the
ensuing  cell death, and demonstrate that the PSD95–
nNOS interface provides a genuine possibility for design
of neuroprotective drugs with increased selectivity.
 
Introduction
 
Glutamate is an essential mediator of excitotoxicity, which is a
form of neuronal death that can occur in a variety of brain regions
subsequent to ischemic insult or other neurodegenerative con-
ditions. Evidence from knockout mice and other models dem-
onstrates the contributions of neuronal nitric oxide synthase
(nNOS) and nitric oxide (NO) to glutamate-induced neuronal
death (Huang et al., 1994; Dawson et al., 1996). The stress-
activated protein kinase p38 is activated within minutes of
glutamate receptor activation, and contributes to glutamate-
induced neurotoxicity (Kawasaki et al., 1997; Cao et al., 2004).
However, the relationship between NO production and p38 in
cell death is unclear, as only delayed p38 activation has been
observed upon application of NO donors to neuronal cells (Lin
et al., 2001; Bossy-Wetzel et al., 2004). The postsynaptic den-
sity protein PSD95 tethers calcium-dependent nNOS to the
mouths of NMDA receptor channels; this selective colocalization
is believed to underlie the source specificity hypothesis, which
states that calcium influx through NMDA receptors is espe-
cially neurotoxic (Aarts and Tymianski, 2003). Thus, complete
ablation of PSD95 with antisense and dissociation of the entire
PSD95 molecule from the NMDA receptor with PDZ1–2 decoy
constructs are neuroprotective in ischemia models (Sattler et
al., 1999; Aarts et al., 2002). Although these results are encour-
aging, PSD95 is known to link a large number of molecules to
the NMDA receptor via its various domains; therefore, PSD95
dissociation/ablation will disrupt additional functions of the
molecule. This disruption may be manifested as side effects.
Indeed, it is unclear which of PSD95’s functions is significant
for the neuroprotection in these reports. The manner in which
PSD95 mediates interaction of NMDA receptors with nNOS is
partly understood. The PDZ1 domain of PSD95 can interact
with the COOH terminus of the NMDA receptor, while PDZ2
is free to bind the NH
 
2
 
-terminal region of nNOS (Niethammer
et al., 1996; Christopherson et al., 1999). Both the nNOS PDZ
domain and the adjacent 
 
 
 
 finger sequence are implicated in
this interaction (Brenman et al., 1996a; Christopherson et al.,
1999; Tochio et al., 2000a).
The possible protective value of the more selective ap-
proach, targeting the PSD95–nNOS interaction itself, has
yet to be examined. In this paper, we initially establish that
glutamate-induced p38 activation and the resulting death of
cerebellar granule neurons involve NO. Thus, nNOS inhibi-
tors prevent the rapid glutamate-induced p38 activation and
 
Correspondence to Michael J. Courtney: courtney@messi.uku.fi
Abbreviations used in this paper: Dea, diethylamine; DIV, days in vitro; FRET,
fluorescence resonance energy transfer; NO, nitric oxide; nNOS, neuronal NOS;
NOS, NO synthase; ONOO
 
 
 
, peroxynitrite; PBD, PSD95-binding domain. 
JCB • VOLUME 168 • NUMBER 1 • 2005 118
 
p38-dependent death. The p38 activation is transient and rap-
idly followed by pyknosis. Consistent with this, neuroprotection
by p38 inhibitor is obtained only when the inhibitor is added
before, and not after, the peak of p38 activation. Consistent
with a role for NO in glutamate-induced cell death, p38 activa-
tion and pyknosis induced by NO donors are as rapid as when
they are induced by glutamate.
Subsequently, we developed a decoy construct based on
nNOS that we could show binds to the PDZ2 domain of
PSD95. This construct prevented p38 activation and neuronal
death induced by glutamate, but not those induced by NO donor.
This suggests that the decoy construct indeed prevents p38
activation and pyknosis upstream of NO synthesis. Similarly,
expression of the free PSD95–PDZ2 domain, which we dem-
onstrate interacts with the NH
 
2
 
 terminus of nNOS, also inhibits
pyknosis. We conclude that development of competitor se-
quences selectively disrupting only the PSD95–nNOS interface
may have value as a neuroprotective strategy in excitotoxicity.
 
Results
 
NO contributes to excitotoxic neuronal cell death (Huang et al.,
1994; Dawson et al., 1996), which can result in neuronal defi-
cits in a variety of brain regions after stroke or the development
other neurodegenerative conditions. Recent evidence suggests
an essential role for the stress-activated protein kinase p38 in
excitotoxic neuronal cell death in cultured cerebellar neurons
(Kawasaki et al., 1997; Cao et al., 2004) and forebrain and hip-
pocampal neurons (Legos et al., 2002), and in vivo in retinal
neurons (Manabe and Lipton, 2003) and cerebral ischemia
(Legos et al., 2001). NO species are known to activate p38 in
nonneuronal cells, but this reportedly depends on a TAB1-
mediated p38 autophosphorylation mechanism (Ge et al., 2002)
that is not required for glutamate-evoked neuronal p38 activa-
tion (unpublished data). Information on the effect of NO on
neuronal p38 is limited—in cerebellar granule neurons, an acti-
vation of p38 after a 3-h incubation with NO donor has been re-
ported (Lin et al., 2001). Because glutamate activates p38
within 2 min and apoptosis is complete within 3 h in these cells
(Cao et al., 2004), the significance of this result has been un-
clear. To consider the possible relationship between NO and
p38, we first investigated in more detail the time course of p38
activation and its requirement for the cell death process. Addi-
tion of glutamate to cerebellar granule neuron cultures leads to
a transient but strong activation of p38 at 5 min, with little ele-
vation above basal level at 30 min and no detectable increase
for the next 3 h (Fig. 1 A). Pyknosis is an early indicator of this
form of cell death, preceding loss of membrane integrity by
several hours (Cao et al., 2004). Cell death, assessed by pykno-
sis, is already detectable 60 min after glutamate addition and is
complete within 3 h (Fig. 1 B). SB203580, at a concentration
that selectively inhibits p38 in intact cerebellar granule neurons
(Coffey et al., 2000, 2002; Cao et al., 2004), is known to pre-
vent this pyknosis. Adding the inhibitor 30 min before the addi-
tion of glutamate strongly prevents the pyknosis, but if the in-
hibitor is added 30 min after glutamate exposure, the pyknosis
is indistinguishable from that in controls (Fig. 1 C). These data
suggest that the early transient increase of p38 activity is im-
portant for glutamate-induced pyknosis.
We subsequently examined the effect of nNOS inhibitors
on p38 activation 5 min after glutamate addition, when phos-
pho-p38 levels are at their highest. 7-Nitroindazole, which does
not discriminate between NOS isoforms (with selectivity ratios
of 0.9–1.4-fold; for review see Alderton et al., 2001), and 
 
N
 
-
 
 
 
-
propyl-
 
L
 
-arginine, which selectively targets nNOS (Zhang et
al., 1997), both substantially and significantly reduced the
glutamate-induced rapid increase in p38 activation loop phos-
phorylation observed at 5 min (Fig. 2, A and B). After this, the
glutamate-induced pyknosis was also significantly diminished,
as expected (Fig. 2, C and D). Both of these inhibitors are com-
petitive with arginine, and thus the effects of the inhibitors are
completely reversed by the presence of excess arginine in the
culture medium (Fig. 2).
If NO species are genuinely involved in glutamate-
induced p38 activation, then NO should, like glutamate, activate
p38 within minutes of addition. Therefore, an NO donor was
added to cerebellar granule neuron cultures and immunoblot-
ting with phospho-p38 antibody was performed on cell lysates
prepared at times after addition of NO donor, as shown (Fig. 3).
We used the NONOate diethylamine/NO adduct (Dea/NO),
Figure 1. Glutamate-induced neuronal death requires the early phase of
p38 activation. (A) Phospho-p38 levels in cerebellar granule neuron extracts
prepared at times indicated after exposure to 50  M glutamate. Phos-
phorylated p38 levels increase rapidly and fall to basal levels from 60
min after glutamate exposure. The pan-p38 blot indicates equal loading of
samples. Means   range are shown (n   2). (B) Pyknosis of cerebellar
granule neurons was assessed at times indicated after the start of a 30-min
glutamate exposure. The pyknosis is complete 2–3 h after exposure to 50
 M glutamate. Means   SEM are shown (n   3). (C) Pyknosis was assessed
3 h after a 30-min glutamate exposure, in the presence of 1  M
SB203580, to specifically inhibit p38, added either 30 min before the
start or immediately after the end of the 30-min glutamate exposure. Only
pretreatment with inhibitor prevented the pyknosis. Means   SEM are
shown (n   3). 
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which degrades with a 
 
t
 
1/2
 
 of 2.1 min (at 37
 
 
 
C), to release NO.
Dea/NO at 250 or 10 
 
 
 
M induced a substantial increase in
phospho-p38 level (Fig. 3, A [top and middle] and B). The
lower concentration is only threefold greater than the amount
used in a recent study to supply a physiologically relevant
amount of NO sufficient to enhance long-term potentiation
without effects on basal synaptic transmission (Bon and Garth-
waite, 2003). The activation of p38 by Dea/NO appears to
occur by a direct effect on the neurons and not by indirect stim-
ulation of glutamate release, because the NMDA receptor an-
tagonist MK801 does not prevent it (unpublished data). It has
been suggested that peroxynitrite (ONOO
 
 
 
) may mediate the
neurotoxic actions of NO. Therefore, we also tested this, at a
concentration reported to activate p38 in 293 cells (Ge et al.,
2002); once again, a rapid p38 activation loop phosphorylation
was detected (Fig. 3, A [bottom] and B). If concentrations of
NO donor sufficient to activate p38 are of relevance to p38-
mediated death by glutamate, then the donors should induce
rapid pyknosis in a manner similar to that of glutamate. Pykno-
sis of cells was measured between 30 and 180 min after addi-
tion of donor, revealing that Dea/NO indeed induces a rapid
pyknosis dependent on the amount of donor added (Fig. 3 C).
The pan-caspase inhibitor zVAD-fmk failed to inhibit p38-
dependent pyknosis induced by glutamate (Cao et al., 2004).
Pyknosis induced by NO and ONOO
 
 
 
 is similar in that zVAD-
fmk fails to prevent it as well (unpublished data).
Based on the experiments just described, we concluded
that glutamate-induced activation of p38 and the subsequent
death of cerebellar granule neurons require activity of nNOS and
can be reproduced with NO donors. PSD95 ablation/dissociation
has been shown to be neuroprotective (Sattler et al., 1999; Aarts
et al., 2002), but as described in the Introduction, it may have ad-
ditional effects. Because hypotheses exist concerning the mech-
anism by which this protein mediates coupling of NMDA recep-
tors to nNOS and the consequent sensitization of the enzyme to
glutamate-mediated calcium influx, we developed a construct
expected to bind PSD95 in a manner identical to, and therefore
competitive with, that of endogenous nNOS. The domain struc-
tures of full length nNOS and the NH
 
2
 
-terminal fragment we
used are shown in Fig. 4 A. This NH
 
2
 
-terminal fragment con-
tains the nNOS PDZ domain and the adjacent 
 
 
 
 finger, both of
which are required for binding PSD95-PDZ2 (Christopherson et
Figure 2. Inhibitors of NOS and nNOS reduce glutamate-
induced p38 activation and pyknosis. (A) Immunoblot
revealing phospho-p38 levels in cerebellar granule neuron
extracts prepared at times indicated, in the presence of
carrier (DMSO) or the pan-NOS– and nNOS-specific
inhibitors 7-Nitroindazole (3  M; 7-NI) and N- -propyl-
L-arginine (1  M; N
w-PLA), respectively. These inhibitors
are competitive with arginine, thus arginine was either
absent, to allow the inhibitors to block the enzyme, or
present, to prevent them from blocking it. Glutamate in-
duces rapid p38 activation; this response is reduced by
pan-NOS– and nNOS-specific inhibitors, but only when
arginine is absent. The pan-p38 blot indicates equal
loading of samples. (B) Replicates of data as in A were
normalized and means   SEM are shown (n   3). Asterisks
indicate significant difference of inhibitor-treated samples
from control by paired t test (P   0.002, or better, in all
cases). (C) Neurons were treated with 50  M glutamate
in the presence or absence of NOS inhibitors and in the
absence or presence of arginine, as shown (conditions
with arginine and inhibitors, but without glutamate, were
not tested). Cells were fixed and DNA stained with
Hoechst 33342, and the inhibitors reduced glutamate-
induced  pyknosis. (D) Replicates of data as in C are
shown as means   SEM (n   6). Asterisk indicates signif-
icant difference of inhibitor treated samples from control
by paired t test (P   0.002, or better, in all cases).
Figure 3. NO species activate neuronal p38 and induce rapid pyknosis.
(A) Application of NO donors, as shown, to neurons increases levels of
phospho-p38, with a time course similar to that induced by glutamate.
The pan-p38 blot indicates equal loading of samples. (B) Replicates of
the data in A were quantified and means   SEM are shown (n   3–4).
(C) Pyknosis of cerebellar granule nuclei was assessed at the times indi-
cated, after application of NO donor Dea/NO at the concentrations
shown. Means   range are shown (n   2). 
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al., 1999; Tochio et al., 2000a), and we therefore named it
nNOS-PBD (PSD95-binding domain). Transfection with GFP
and GST fusion constructs leads to expression of a protein run-
ning at 
 
 
 
70 kD (Fig. 4 B and not depicted). To investigate
whether this construct is able to selectively bind PSD95-PDZ2,
we cotransfected GST-tagged nNOS-PBD into COS7 cells with
GFP-tagged PSD95-PDZ1, PSD95-PDZ2, or PSD95-PDZ3, or
GFP alone. Pull-down of nNOS-PBD with immobilized glu-
tathione revealed that a selective interaction had formed within
intact cells with PDZ2 but not PDZ1, PDZ3, or unfused GFP
(Fig. 4 C), and that this interaction was sufficiently stable to be
detected after cell lysis and multiple washing steps.
The purpose of producing the nNOS-PBD construct was
to prevent glutamate-induced activation of p38 and the resulting
cell death. Therefore, we investigated whether the construct was
capable of doing this. Cerebellar neuron cultures were cotrans-
fected with empty vector or nNOS-PBD together with GST-
tagged p38. Thus, we were able to selectively recover p38 from
transfected neurons with glutathione immobilized on beads. In
the presence of empty vector, the recovered p38 exhibited a
large increase in activation loop phosphorylation in response to
glutamate. However, the presence of cotransfected nNOS-PBD
substantially reduced the p38 activation (Fig. 5, A and B). Sub-
sequently, neurons were transfected with nNOS-PBD or empty
vector together with GFP marker plasmid so that the transfected
cells could be identified. Glutamate induced pyknosis in 
 
 
 
50%
of neurons in the presence of empty vector, but the presence of
nNOS-PBD greatly reduced this response (Fig. 5, C and D).
Next, we considered whether nNOS-PBD inhibits glu-
tamate-induced p38 activation and cell death by acting up-
stream or downstream of NO. Neurons were challenged with
NO donor as in Fig. 2, and p38 from transfected cells showed a
large increase in phosphorylation that was not prevented by
cotransfection with PBD (Fig. 6, A and B). NO donor–induced
pyknosis was also not prevented by transfection with nNOS-
PBD (Fig. 6 C).
The nNOS-PBD construct was designed to selectively in-
terfere with the NMDA receptor–PSD95 complex. Thus, it was
important to evaluate whether it perturbed the general properties
of the NMDA receptors, other than nNOS-dependent p38 acti-
vation. Patch-clamp recordings of whole-cell currents induced
by the rapid application of NMDA applied via a U-tube showed
that cells transfected with either nNOS-PBD or vector control
were indistinguishable (Fig. 7 A). We detected no significant
Figure 4. nNOS-PBD selectively and stably interacts with the PSD95-
PDZ2 domain. (A) Domain map of nNOS  (1,433 aa in length). The PDZ
and   finger ( ƒ) domains have been reported to interact with the NMDA
receptor scaffold PSD95, leading to the hypothesis that this interaction
may confer on NMDA receptors an increased propensity to produce NO.
The synthetic construct nNOS-PBD (PSD95-binding domain; amino acids
1–300), which incorporates all sequences reported to be required for
PSD95 interaction, is also shown. (B) The epitope-tagged construct GFP-
nNOS-PBD expresses a single species of the expected migration in 293
cells. The positions of calibrated molecular mass markers are shown on the
left. (C) The selectivity and stability of the interaction between PSD95-PDZ
domains and nNOS was monitored by coprecipitation of the PDZ domains
with GST-tagged nNOS-PBD, using glutathione immobilized on beads.
COS7 cells were cotransfected with GST-nNOS-PBD and GFP-tagged
PSD95-PDZ1, PSD95-PDZ2, or PSD95-PDZ3, or empty GFP vector (GFP),
as indicated. Only PDZ2 was revealed by anti-GFP immunoblotting of the
washed beads (pull-down, bottom). The input blot (top) shows that equal
amounts of GFP fusion proteins were expressed in the different cell lysates,
and the anti-GST pull-down blot (middle) shows that equal amounts of GST-
nNOS were captured from the lysates by the beads.
Figure 5. nNOS-PBD inhibits glutamate-evoked activation of p38  and
subsequent pyknosis. (A) Neurons were cotransfected with p38  and
nNOS-PBD or empty vector (pCMV), as indicated. Cells were stimulated
with glutamate or control, p38  was collected from the transfected cell
population, and activation was detected with phospho-specific antibodies.
Glutamate activated transfected p38 , and the presence of nNOS-PBD
reduced this activation. Immunodetection of total p38 with pan-p38 anti-
body demonstrates equal loading. (B) Replicates of the data in A were
quantified and means   SEM are shown (n   3). Asterisk indicates signif-
icant difference from empty vector–transfected glutamate-treated samples
by paired t test (P   0.01). (C) Neurons were transfected with nNOS-PBD
(PBD) or empty vector (pCMV), together with GFP as a transfection
marker, and treated with control or for 30 min with 50  M glutamate.
After 3 h, cells were fixed and DNA stained with Hoechst 33342, to allow
assessment of pyknosis. GFP and Hoechst images are shown, as indicated.
The nNOS-PBD reduced the glutamate-induced pyknosis. Transfected neu-
rons with normal nuclei are indicated by arrows, and transfected neurons
with pyknotic nuclei are indicated by arrowheads. (D) Replicates of data
as in C are shown as means   SEM (n   3). Asterisk indicates significant
difference from empty vector–transfected glutamate-treated samples by
paired t test (P   0.001). 
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differences in induced current amplitude (Fig. 7 B, left) or time
to peak current (Fig. 7 B, right). Capacitance was also un-
changed (unpublished data), which suggests that no gross alter-
ations in cell structure were induced. NMDA receptor activity
leads to calcium influx into the cell. However, the actual
changes in cytoplasmic free calcium also depend on the cal-
cium-handling machinery of the cell. We measured the calcium
response of cells transfected with nNOS-PBD or vector con-
trol by cotransfecting a fluorescence resonance energy trans-
fer (FRET)–based calcium reporter “precocious cameleon,” or
YC2.12 (Nagai et al., 2002). Once again, the nNOS-PBD– and
vector-transfected cells were indistinguishable (Fig. 7 C).
Together, these data support the proposal that the nNOS-
PBD construct reduces glutamate-induced p38 activation and
pyknosis by acting upstream of NO production, without caus-
ing general perturbation of either the electrophysiological
characteristics of the NMDA receptor or the downstream sig-
naling pathways. This suggests that a protein sequence that in-
teracts with PSD95 in the same way as nNOS may be suffi-
cient to confer significant neuroprotection via inhibition of
glutamate-evoked p38 activation. Conversely, it would be ex-
pected that the PSD95-PDZ2 domain, which binds nNOS se-
quences (Fig. 4 C), would also be capable of conferring neuro-
protection, whereas PDZ3 would not. PDZ1 may also be
expected to be neuroprotective via interaction with the COOH
termini of NMDA receptor subunits, but this interaction can
be anticipated to dissociate PSD95 from the receptor complex
and, therefore, to nonspecifically affect all aspects of NMDA
receptor–PSD95 function. It is possible that the free PDZ2 do-
main may also act in this way, as PDZ2 is able to interact in
vitro and in yeast with COOH-terminal peptide sequences de-
rived from several NMDA receptor subunits (Niethammer et
al., 1996), but those NMDA receptors that associate via
PSD95 to nNOS may do so only via NMDA receptor interac-
tion with PDZ1, because PDZ2 mediates the interaction with
nNOS (Christopherson et al., 1999). We investigated the abil-
ity of glutamate to evoke pyknosis of cells transfected with
the constructs shown in Fig. 4 C; i.e., either PSD95-PDZ1,
PSD95-PDZ2, PSD95-PDZ3, or empty epitope vector (un-
fused GFP). Both PDZ2 and PDZ1 conferred neuroprotection,
but PDZ3 failed to protect (Fig. 8).
 
Discussion
 
Excitotoxic neuronal death is the consequence of overstimula-
tion of glutamate receptors, which leads to excessive calcium
influx. Excitotoxicity is believed to contribute to disorders such
as ischemia, traumatic brain injury, Parkinson’s disease, Hunt-
ingdon’s disease, Alzheimer’s disease, and amyotrophic lateral
sclerosis. The calcium influx causes induction of NO produc-
tion by the nNOS that is activated by binding of calcium–cal-
modulin (for review see Alderton et al., 2001). As a result, sev-
eral different NO species may be produced, and these have
been reported to have either neuroprotective or neurotoxic con-
sequences (for review see Nelson et al., 2003). In spite of this
complexity, there is evidence that nNOS contributes to ische-
mic cell death. For example, targeted deletion of the second
Figure 6. nNOS-PBD does not prevent NO-
evoked activation of p38  or subsequent
pyknosis. (A) Neurons were cotransfected
with p38  and nNOS-PBD or empty vector
(pCMV), as indicated. Cells were stimulated
with 10  M Dea/NO as NO donor (as de-
scribed in the Fig. 3 legend), or with control,
p38  was collected from the transfected cell
population, and activation was detected with
phospho-specific antibodies. Dea/NO acti-
vated transfected p38 , but the presence of
nNOS-PBD did not reduce this activation.
Immunodetection of total p38 with pan-p38
antibody demonstrates equal loading. (B)
Replicates of the data in A were quantified
and means   SEM are shown (n    3) (C)
Neurons were transfected with nNOS-PBD
(PBD) or empty vector (pCMV), together with
GFP as a transfection marker, as described in
the Fig. 5 (C and D) legend, and then treated
with Dea/NO. The nNOS-PBD did not affect
the Dea/NO-induced pyknosis. Means  
SEM (n   3) are shown.
Figure 7. nNOS-PBD does not perturb NMDA receptor electrophysiological
characteristics or NMDA-induced calcium response. (A) Whole-cell currents
recorded from neurons transfected with GFP-tagged nNOS-PBD or pEGFP-C1
vector as control, after the rapid (U-tube) application of 200  M NMDA,
where indicated. To isolate NMDA receptor–gated currents, the U-tube
solution contained tetrodotoxin, bicuculline, and NBQX, together with
D-serine to saturate the glycine site, in addition to NMDA. (B) Peak current
density (left) and time to peak current (right) were calculated from repli-
cates, and means   SEM are shown. (C) Neurons were cotransfected with
FRET-based calcium probe YC2.12, together with either nonfluorescent
pEBG-nNOS-PBD or pEBG vector control, as indicated. Cells were excited
with 440 nm and images were acquired alternately at 480 nm (CFP emis-
sion) and 530 nm (raw FRET signal). 100  M NMDA was added at time 0.
Data are expressed as FRET ratio, i.e., raw FRET signal/CFP emission
signal, which increases as calcium levels rise, bringing the fluorophores
closer to one another and thereby increasing the FRET signal and
quenching the CFP. 
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exon of nNOS that contains the 
 
 
 
 isoform start codon elimi-
nates expression of the nNOS
 
 
 
 isoform without affecting 
 
 
 
and 
 
 
 
 isoforms. The resulting nNOS
 
 
 
 
 
/
 
 
 
 mice exhibit a re-
duced sensitivity to ischemic neuronal death (Huang et al.,
1994) and reduced NMDA-induced death of cortical cultures
(Dawson et al., 1996). In addition, small molecule nNOS in-
hibitors have neuroprotective actions (for review see Chab-
rier et al., 1999). Several mechanisms, including activation of
poly(ADP-ribose) polymerase, inhibition of cytochrome 
 
c
 
 oxi-
dase and other mitochondrial proteins, release of free cytoplas-
mic zinc, and activation of Trp channels, have been suggested
to contribute to NO-induced neurodegeneration (Brown and
Borutaite, 2002; Aarts et al., 2003; Bossy-Wetzel et al., 2004;
for review see Yu et al., 2003). However, it is not clear whether
these mechanisms are independent, interacting, or whether they
form part of a single neurodegenerative pathway, and to what
extent p38 is involved in these processes.
Thus, inhibition of nNOS can be expected to reduce exci-
totoxicity. However, this alone does not imply that PSD95–
nNOS interaction is necessary or important for neurotoxicity,
nor whether p38 might mediate a neurotoxic consequence of
this interaction. The source specificity hypothesis states that
calcium influx through NMDA receptors is especially neuro-
toxic (Aarts and Tymianski, 2003; Hardingham and Bading,
2003). This has been interpreted as a consequence of PSD95-
mediated coupling of NMDA receptors and nNOS. The expec-
tation that disrupting PSD95–nNOS interaction would have
neuroprotective benefit is based on the validity of these hy-
potheses and assumptions. The mechanism of PSD95–nNOS
interaction has been well characterized, and atomic detail is
available from nuclear magnetic resonance structure and mo-
lecular modeling studies (Tochio et al., 2000b). Such data may
aid possible development of small molecule compounds target-
ing this interaction. It is of interest to note that, even in the ab-
sence of small molecule inhibitors, the use of cell-permeable
peptides has recently proven to be a realistic approach to reduc-
ing cell death in animal models of excitotoxicity (Aarts et al.,
2002; Borsello et al., 2003). However, the possible neuropro-
tective value of targeting the PSD95–nNOS interface has been
unexplored. Although ablating PSD95 or uncoupling it from
the NMDA receptor provides substantial neuroprotection in an
ischemia model (Sattler et al., 1999; Aarts et al., 2002), PSD95
is a multidomain protein believed to be a central mediator of
assembly of the postsynaptic density complex, consisting of a
vast array of signaling and structural molecules coupled to
glutamate receptors in these specialized regions of neuronal
cells (Husi et al., 2000). Thus, complete removal of PSD95 can
be anticipated to have consequences beyond the dissociation of
nNOS from the NMDA receptor (Aarts and Tymianski, 2003),
thereby bringing with it the potential for undesirable side ef-
fects. The neuroprotective effects of PSD95 ablation or dissoci-
ation in the ischemia model may be the result of uncoupling of
nNOS from glutamate-evoked calcium influx, but this remains
unclear (Aarts and Tymianski, 2003). Further investigation of
this issue is required before any firm conclusions can be drawn,
and the source specificity hypothesis itself remains controver-
sial (Hardingham and Bading, 2003). Any evidence that sug-
gests a neuroprotective value of disrupting the PSD95–nNOS
interface may have therapeutic importance, as it would increase
the number of possible drug targets that could be considered
for diseases involving excitotoxicity. It is anticipated that an
improved clinical outcome, an increased primary effect, and
fewer side effects might be obtained by aiming at more than
one target in disease-causing signaling pathways. Furthermore,
agents that disrupt the interaction between nNOS and PSD95
possess increased specificity, compared with small molecule
catalytic site inhibitors, for two reasons: (1) only the 
 
 
 
 isoform
of nNOS can interact with PSD95, whereas the catalytic do-
mains are identical in the other isoforms (for review see Alder-
ton et al., 2001), which will be unaffected by the aforemen-
tioned strategy; and (2) only the functions of the   isoform that
are dependent on its interaction with PSD95, e.g., coupling to
calcium influx through NMDA receptor, will be inhibited, as
the nNOS  enzyme will not otherwise be affected.
In this study, we considered whether the PSD95–nNOS
interface might be a suitable target for neuroprotective agents
and whether the p38 pathway might mediate PSD95–nNOS
interaction–dependent cell death. We chose a model of glu-
tamate-induced neuronal death that we have characterized
in some detail (Cao et al., 2004). Excitotoxicity can affect a va-
riety of different brain regions and contribute to several neuro-
degenerative conditions. The morphological and biochemical
features of degenerating neurons suggest that multiple mecha-
nisms may underlie this form of cell death, even within a single
brain region under a single stress, such as in ischemic cerebral
cortex (Fukuda et al., 1999; Didenko et al., 2002). More effec-
tive neuroprotection will result from an understanding of dif-
ferent forms of neuronal cell death, which requires the use of
multiple model systems. Glutamate-induced death in the cere-
bellar granule neuron model is NMDA receptor dependent and
has properties (Cao et al., 2004; for review see Yu et al., 2003)
reported to be associated with excitotoxic death in several other
systems, including cultured cortical neurons and the ischemic
brain. These properties include lumpy chromatin condensation
(Sohn et al., 1998; Fukuda et al., 1999; Didenko et al., 2002),
caspase independence (Didenko et al., 2002; Yu et al., 2002),
insensitivity to inhibitors of transcription and translation (Cser-
nansky et al., 1994; Lobner and Choi, 1996; Gwag et al., 1997),
sensitivity to p38 inhibition (Legos et al., 2001, 2002), involve-
ment of NO or nNOS (Huang et al., 1994; Dawson et al.,
1996), and sensitivity to poly(ADP-ribose) polymerase inhibi-
tion (for review see Yu et al., 2003). Thus, the cerebellar gran-
ule neuron model may be particularly useful for studying forms
of excitotoxic cell death with these properties.
Figure 8. Free PDZ1 and PDZ2 domains in-
hibit glutamate-induced death, but PDZ3 has
no effect. Neurons were transfected with the
GFP-tagged PSD95-PDZ domains described in
the Fig. 4 C legend, or empty vector, and then
treated with glutamate or not treated. Pyknosis
of transfected cells was assessed as described
in the Fig. 5 (C and D) legend. Replicates were
quantitated and means   SEM are shown (n   3). Asterisk indicates a sig-
nificant difference between cells transfected with GFP-PDZ1 or GFP-PDZ2,
compared with empty vector pCMV, by paired t test (P   0.005, or better).P38 INHIBITION AND NEUROPROTECTION BY nNOS-PBD • CAO ET AL. 123
Here, we demonstrated that the p38 activation and cell
death in glutamate-treated cerebellar granule neurons were both
sensitive to inhibitors of NOS and nNOS. Subsequently, we
demonstrated that NO donor was capable of activating p38 and
cell death in this model in a manner strikingly similar to the
way glutamate induces death. This is consistent with the pro-
posal that glutamate-induced cell death in this model involves
generation of NO, a predictable but necessary prerequisite for
this model to be useful for considering the possible neuropro-
tective value of targeting the PSD95–nNOS interaction. It is
important to note that an additional prerequisite is the validity
of the source specificity hypothesis, for if neurotoxicity were
dependent merely on calcium load and not on localization, then
nNOS would continue to contribute to neurotoxicity even if no
longer physically associated with the NMDA receptor. nNOS
activity also appeared to be necessary (and sufficient) for the
activation of p38 that is critical for glutamate-evoked cell death
(Fig. 9 A). Therefore, any neuroprotection that is the result of
disrupting the PSD95–nNOS interface should inhibit glu-
tamate-evoked p38 activation as well as cell death.
The NH2-terminal region of nNOS  we used, nNOS-
PBD, selectively and stably bound PDZ2, as expected (Fig. 4).
Expression of this construct in neurons inhibited p38  activa-
tion and reduced the subsequent cell death induced by glutamate
treatment. This suggests that nNOS-PBD binds to a target in
neuronal cells that is necessary for glutamate-induced p38 acti-
vation and subsequent cell death. The normal electrophysiologi-
cal characteristics of the NMDA receptors and the cells’ cal-
cium response to NMDA were unaffected, which suggests that
the action of nNOS-PBD was specific to the NMDA receptor–
p38 pathway. The simplest explanation is that it is PDZ2 of
PSD95 (or related molecules such as PSD93; Brenman et al.,
1996b) that is affected in these experiments, leading to inhibi-
tion of the PSD95–nNOS interaction (Fig. 9 B). Because only
a small amount of nNOS immunostaining colocalized with
PSD95 immunostaining in these cells (unpublished data) and
microscopy does not have sufficient resolution to discern dis-
ruption of the physical interaction between the molecules, it was
not possible for us to directly visualize this effect. Instead, we
reasoned that if the nNOS-PBD acts by preventing interaction of
PSD95 (or a related molecule) with nNOS, thereby preventing
NO production and the downstream consequences, then it
should be possible to bypass this effect by exogenously supply-
ing NO, which we had already demonstrated induced cell death
in a manner very similar to that induced by glutamate. Indeed,
transfection with nNOS-PBD had no effect on NO-induced acti-
vation of p38 or the subsequent neuronal death (Fig. 9 C). We
sought additional evidence for the role of this interaction by
generating expression of PDZ2 to compete with endogenous
PSD95 in the nNOS interaction, or of PDZ3 as a control. PDZ2
again inhibited glutamate-induced neuronal cell death, whereas
PDZ3, which is not known to have any importance in glu-
tamate-induced neuronal cell death, had no effect (Fig. 9 D,
middle and right). PDZ1 was also somewhat protective. This is
not surprising, because PDZ1 can interact with the COOH ter-
mini of subunits of the NMDA receptor complex (while, si-
multaneously, PDZ2 can bind nNOS; Christopherson et al.,
1999), thereby dissociating the entire PSD95 molecule from the
NMDA receptors (Aarts and Tymianski, 2003; Fig. 9 D, left).
In conclusion, these results suggest that the interaction
between nNOS and PSD95 (or a related molecule such as
PSD93) is important for glutamate-induced activation of p38 
stress-activated protein kinase and the ensuing cell death, and
that the nNOS–PDZ2 interface is a target suitable for neuro-
protective drug design efforts. It can be anticipated that, com-
pared with agents that dissociate PSD95 from NMDA receptors,
such reagents will have less effect on the NMDA receptor–
PSD95 interaction and thus will produce considerably lower
disruption of the delicate and highly complex postsynaptic
density apparatus.
Figure 9. A hypothetical model proposed to
explain the disruption of neuronal death sig-
naling revealed by the constructs investigated.
(A) In an untransfected neuron, PSD95 is re-
portedly able to bring nNOS in close proximity
to the calcium pore of the NMDA receptor. As
a result, glutamate induces activation of nNOS
and, subsequently, of p38. (B) The presence
of nNOS-PBD in transfected cells (in excess of
endogenous PSD95) competes with and pre-
vents interaction of endogenous nNOS with
PSD95, leading to a reduced ability of
glutamate to activate p38 and pyknosis, which
supports the source specificity hypothesis. (C)
However, the presence of nNOS-PBD has no
effect on the responses to addition of exoge-
nous NO as this bypasses the requirement for
PSD95–nNOS interaction. (D) Related scenar-
ios in the presence of transfected PDZ1, 2 or
3. PDZ1 is reportedly capable of interacting
with the NMDA receptor not nNOS, but this
too reduces the ability of glutamate to in-
duce pyknosis. PDZ2 is more effective, mim-
icking nNOS-PDZ2 in its actions, whereas
PDZ3 reportedly interacts neither with NMDA
receptor nor with nNOS, which explains its
failure to prevent glutamate-induced pyknosis.JCB • VOLUME 168 • NUMBER 1 • 2005 124
Materials and methods
Antibodies and plasmids
Mouse anti-GFP (CLONTECH Laboratories, Inc.), rabbit anti–phospho-p38
(New England Biolabs, Inc.) and mouse anti–pan-p38 (Transduction Labs)
were used with secondary reagents from various sources (Santa Cruz Bio-
technology, Inc. and UBI). The coding sequence for the NH2-terminal 300
amino acids of nNOS was prepared by PCR-based methods from plasmid
pPIC-ZA-nNOS (a gift from Bernt Mayer, Karl-Franzens-Universitat, Graz,
Graz, Austria) and inserted in-frame with the GFP coding sequence of the
plasmid pEGFP-C1 (CLONTECH Laboratories, Inc.) to make GFP-nNOS-
PBD. pEBG-nNOS-PBD was prepared by inserting the same sequence into
the plasmid pEBG (a gift from Bruce Mayer, University of Connecticut
Health Center, Farmington, CT) in-frame with the GST coding sequence.
PDZ domains from PSD95 were PCR amplified from the plasmid pCMV-
PSD95 (a gift from Y. Hata, Osaka University Medical School, Suita,
Osaka, Japan). PDZ1 (aa 60–155), PDZ2 (aa 155–249), and PDZ3 (aa
302–402) were subsequently inserted in-frame into the plasmid pEGFP-
C1. pEBG-p38  was a gift from Bruce Mayer. pCMV was a gift from S.
van den Heuvel (Massachusetts General Hospital, Boston, MA).
Cell culture and glutamate and NO donor treatment
Primary cultures of cerebellar granule neurons were prepared and main-
tained as described previously (Courtney et al., 1997). Neurons used
were cultured for 7–9 d in vitro (DIV). Glutamate treatment was performed
as described previously (Cao et al., 2004). Cells were briefly rinsed in
Mg-free Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 3.6 mM NaHCO3,
1.3 mM CaCl2, 5.6 mM D-glucose, and 5 mM Hepes, pH 7.4) and placed
in the same buffer with glutamate (50  M) for 30 min, or as shown in the
legend of Fig. 1; 10  M glycine was routinely included with glutamate be-
cause it is an essential coagonist for the NMDA receptor. Subsequently,
cells were rinsed in Locke’s buffer with 1 mM MgCl2, and conditioned me-
dium was replaced for the times indicated in the legends of Fig. 1; Fig. 3
C; Fig. 5, C and D; Fig. 6 C; and Fig. 8. NO treatment was performed by
adding 10 or 250  M NO donor Dea/NO (DeaNONOate) or 300
 M ONOO
  to the cell culture media directly, and these conditions
were maintained throughout the whole experiment. The concentration of
ONOO
  was determined by measuring its absorbance at 302 nm (   
1,670 M
 1 cm
 1). The concentration of ONOO
  was measured for every
experiment, just before it was added to the samples. Pharmacological
agents (3  M 7-Nitroindazole, 1  M N- -propyl-L-arginine, and 1  M
SB203580) were added 60 min before glutamate treatment, and the
agents were also present in all media in which the cells were subsequently
incubated. The NOS inhibitors are competitive with arginine; therefore,
cells were placed in arginine-free conditions during the period of incuba-
tion with these inhibitors (or incubation with carrier, in the case of con-
trols). 1 mM arginine was added to the preincubation and stimulation so-
lutions, where indicated in the legend of Fig. 2.
Immunoblotting
Immunoblotting was performed as described previously (Coffey et al.,
2002) by treating cells as indicated (see legends of Fig. 1 A; Fig. 2, A
and B; Fig. 3, A and B; and Fig. 4 B), rinsing rapidly in ice-cold PBS, lys-
ing in 1  Laemmli buffer, boiling, clearing, resolving by SDS-PAGE, and
performing electrotransfer. Western blotting was performed according to
standard protocols, and blots were developed using ECL reagents accord-
ing to the manufacturer’s instructions.
Cell death assay
After treatment as described in the Cell culture and glutamate and NO do-
nor treatment section (typically after 3 h or as indicated in the legends of
Figs. 1 B and 3 C), cells were stained with Hoechst 33342, fixed, and
scored on the basis of nuclear morphology. A pyknotic nucleus was con-
sidered to indicate death of the cell.
Pyknosis assay for transfected neurons
Cerebellar granule cultures at 6–7 DIV were transfected as described previ-
ously (Coffey et al., 2000). They were cotransfected with GFP marker plas-
mids and either empty vector (pCMV), GFP-nNOS-PBD, GFP-PSD95-PDZ1,
GFP-PSD95-PDZ2, or GFP-PSD95-PDZ3. When tested, cotransfection effi-
ciency was almost 100% (Coffey et al., 2002; Hongisto et al., 2003). 24 h
after transfection, cells were treated with or without glutamate or NO do-
nor Dea/NO as described in the Cell culture and glutamate and NO do-
nor treatment section. 3 h after stimulation, cells were fixed with 4% PFA,
rinsed with ice-cold PBS, and stained with Hoechst 33342. For transfected
neurons, fluorescence image fields of GFP emission using 450–490 nm of
excitation light and a 20  air objective were taken to locate transfected
cells, and the corresponding image of Hoechst fluorescence was examined
to determine whether transfected cells had pyknotic nuclei. Four evenly
spaced fields were counted per coverslip. Imaging of DNA dyes and trans-
fected fluorescent proteins was performed with a cooled CCD (model
KX85; Apogee) under control of MicroCCD software (Diffraction Limited)
and a microscope (model IX70; Olympus) with a 20  air objective (0.4
NA) and appropriate filter cubes.
Assay for activation of transfected p38 
7 d after plating in 35-mm dishes, cerebellar granule neurons were co-
transfected with EBG-p38  and either empty vector (pCMV) or GFP-
nNOS-PBD. 24 h after transfection, cells were treated as described in the
legends of Figs. 5 and 6 for 5 min, rinsed once with ice-cold PBS, and
lysed in 500  l of lysis buffer (20 mM Hepes, pH 7.4; 2 mM EGTA; 50
mM  -glycerophosphate; 1 mM DTT; 1 mM Na3VO4; 1% Triton X-100;
10% glycerol; 50 mM NaF; 1 mM benzamidine; 1  g/ml aprotinin, leu-
peptin, and pepstatin; and 100  g/ml PMSF). Homogenized and pre-
cleared supernatants were incubated with 10  l (bed volume) prewashed
S-hexylglutathione agarose beads for 3 h at 4 C. Beads were spun out
and washed three times in lysis buffer, and then the drained beads were
boiled in 40  l 1  Laemmli sample buffer, for immunoblotting.
Pull-down assay for PSD95–nNOS interaction
1 d after plating in 10-cm dishes, COS7 cell cultures were cotransfected
with EBG-nNOS-PBD and either GFP-PDZ1, GFP-PDZ2, GFP-PDZ3, or GFP-
C1. After 48 h of transfection, cells were rinsed once with ice-cold PBS and
lysed in 800  l of low-salt buffer (20 mM Na2  -glycerophosphate; 30 mM
NaF; 2 mM EDTA; 2 mM Na4P2O5; 1 mM DTT; 10  g/ml aprotinin, leu-
peptin, and pepstatin A; 0.5 mM AEBSF; and 0.5% igepal). Homogenized
and precleared supernatants were rotated for 3 h at 4 C with 15  l
(bed volume) S-hexylglutathione agarose beads preequilibrated in low-salt
buffer. Beads were spun out and washed three times in the same buffer,
and then the aspirated pellet was boiled in 50  l 1  Laemmli sample
buffer for immunoblotting.
Electrophysiological recordings
Whole-cell currents were recorded from single cultured cerebellar granule
cells (at 7 DIV) and transfected with either pEGFP-C1 (empty vector) or the
PSD95-PDZ2–binding region of nNOS (pEGFP-nNOS) using an amplifier
(Axopatch 200B; Axon Instruments, Inc.). Recorded membrane currents
were digitized using a Digidata 1320A interface (Axon Instruments, Inc.)
and analyzed using pCLAMP software. Patch pipettes were pulled from
thin-wall borosilicate glass (1.5-mm outer diameter and 1.17-mm inner di-
ameter; Clarke Electromedical) and fire polished to give a final resistance
of  5 M  when filled. The pipette-filling solution contained (mM): 145
potassium gluconate, 10 Hepes, 5 EGTA, 5 MgCl2, 5 Na2ATP, and 0.2
GTP; adjusted to pH 7.2. The extracellular solution contained (mM): 145
NaCl, 5 KCl, 1 CaCl2, 5 Hepes, 5 glucose, and 20 sucrose; adjusted to
pH 7.4. NMDA receptor currents were elicited at a holding potential of
 60 mV by the rapid (U-tube) application of 200  M NMDA in extracel-
lular solution containing 20  M D-serine, 50  M bicuculline, 1  M tetro-
dotoxin, and 5  M NBQX.
FRET-based imaging of cytoplasmic free calcium
Cerebellar granule neurons were cultured on 10-mm square glass cover-
slips and cotransfected at 6–7 DIV with the precocious cameleon YC2.12
(a gift from A. Miyawaki, RIKEN Brain Research Institute, Wako, Japan;
Nagai et al., 2002) and pEBG vector or pEBG-nNOS-PBD, as indicated
in the legend of Fig. 7 C. This calcium probe is based on the Venus YFP
variant that is most resistant to changes in pH and chloride, and matures
quickly, thereby avoiding artifactually low FRET caused by retarded matu-
ration of the acceptor fluorophore. The following day, the coverslips were
washed once in Locke’s buffer with 1 mM MgCl2 and twice more in
Locke’s buffer without MgCl2, and then placed in 1 ml of Locke’s buffer
without MgCl2 in a chamber on a microscope (model IX70; Olympus).
Cells were illuminated with a mercury lamp, a neutral density filter, and a
440 nm/21 nm excitation filter. CFP and YFP emission image pairs were
acquired (with a 2-s integration time per channel and 13 s between image
pairs) through a 455-nm dichroic mirror and 480 nm/30 nm and 530
nm/26 nm filters in a filter wheel (CVI laser; Apogee Instruments, Inc.)
mounted parfocally in front of a cooled CCD (model KX85; Apogee Instru-
ments, Inc.). The acquired CFP emission images represent CFP signals
quenched by FRET, and are referred to hereafter as CC images. The ac-
quired Venus YFP emission images represent raw FRET signals, and are re-
ferred to hereafter as CY images. As calcium rises, it causes the probe toP38 INHIBITION AND NEUROPROTECTION BY nNOS-PBD • CAO ET AL. 125
fold to a more compact conformation, leading to increased CY signal and
quenching the CC signal. The ratio of background-corrected CY and CC
signals was calculated and is directly related to calcium changes. NMDA
and glycine (at final concentrations of 100  M and 10  M, respectively)
were added at time 0. FRET time courses (CY/CC ratio) were calculated
from the acquired image series with image analysis software developed
by the authors (Lindqvist et al., 1995) that had been modified to permit
the processing of these image datasets as just described. Background-cor-
rected fluorescence ratio time courses were normalized to the average
prestimulation CY/CC ratio values for each cell, the means of cells within
each field were calculated, and the data are presented in Fig. 7 C as
means   SEM of independent experiments.
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